Navigation Links
Proteonomix Announces a Private Placement of $3.8 Million
Date:3/6/2012

se of the warrants and conversion of the preferred stock. Any offering of the Company's securities under the resale registration statement referred to above will be made only by means of a prospectus.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the transaction.

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors.

This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

Further details of the placement will be described in a Current Report on Form 8-K to be filed with the SEC by the Company and all of the transaction documents will be attached to the Form 8-K. 

About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). Proteonomix Regenerative Translational
'/>"/>

SOURCE Proteonomix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
2. ARUP Laboratories Announces Creation of Business Innovations Division
3. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
4. Regeneron Announces March 2012 Investor Conference Presentations
5. MiMedx Group Announces 2011 Results
6. Pro-Dex, Inc. Announces the Sale Of Its Motor Business
7. PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
8. Innocoll Announces Successful End-of-Phase 2 Meeting with FDA for XaraColl® and Agreement of the Phase 3 Program
9. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
10. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
11. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... this case, a set of miniaturized chemical reaction areas on ... and/or antibodies. These new patents from Able Signal Company LLC ... important new capabilities in the area of genomics and genome ... patents will be auctioned off at ICAP Ocean Tomo,s ...
... HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) will release financial ... 2010 prior to the open of the U.S. stock markets ... with management is scheduled for 8:00 am U.S. Eastern Standard ... Daylight Time, between February 24 and February 25, 2011) to ...
... 2011 Reportlinker.com announces that a new market ... Pipeline Insight: Cancer Overview- Breast and ... positive patients http://www.reportlinker.com/p0386436/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html ... three tumor types covered in this report are ...
Cached Biology Technology:Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis 2HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results 2Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Michigan State University researcher will travel to Siberia to ... is adapting to global change. Siberia,s Lake Baikal, ... as the world,s largest (by volume) and most-diverse lake. ... web endemic to Baikal with organisms that are highly ...
... had a category for the largest human-designed protein, then a ... They have designed and successfully synthesized a variant of ... acid histidine. It is more than twice the size of ... the University of Washington in 2003. The synthetic protein, ...
... New research released today demonstrates the brain,s remarkable ... ways to prevent or limit damage after blood and ... 2011, the Society for Neuroscience,s annual meeting and the ... and health. Stroke is the number one cause ...
Cached Biology News:MSU researcher sent to Siberia to study global change 2Creation of the largest human-designed protein boosts protein engineering efforts 2Creation of the largest human-designed protein boosts protein engineering efforts 3Brain, repair thyself: Studies highlight brain's resiliency to damage 2
... an ~185 kDa protein, corresponding to the ... tyrosine 1248 on SDS-PAGE immunoblots. The affinity ... the non-phosphorylated peptide to remove antibodies that ... protein. In cell lines where EGFR ...
... Cyclin D2 is a G1 cyclin required ... candidate for a proto-oncogene. cyclin D2 ... and/or cdk6. Species Reactivity: Human, Mouse, ... DCS-3.1 MAb is particularly well suited for ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
Biology Products: